Ariad Pharmaceuticals, Inc. (ARIA), Pfizer Inc. (PFE), Celgene Corporation (CELG): Who’s The Best?

Celgene Corporation (NASDAQ:CELG) became Foundation’s second large partner in May 2011. The goal for Celgene Corporation (NASDAQ:CELG) was to use Foundation’s cancer genomic tests to speed up the recruitment process for target patients and identify those patients most likely to respond to Celgene Corporation (NASDAQ:CELG)’s experimental drugs. This relationship also seems to be going well, since Celgene-backed Agios Pharmaceuticals also struck a deal just last month for a multi-year partnership.

Foundation went on to line up other significant partners. Johnson & Johnson (NYSE:JNJ), Sanofi SA (ADR) (NYSE:SNY), and the aforementioned Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) are just a few companies developing cancer drugs that now rely on Foundation’s technology.

More tech
These aren’t the only companies that put the “tech” in “biotech” by any stretch. Other companies use the 3-D modeling and structural drug design process employed by Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA). There are plenty of other examples of end-result technology as impressive as that of Acura. Foundation Medicine isn’t the only player in the fast-growing world of genomic testing. However, these are good examples of the impact that technology is having in a sector with technology as part of its name. Biotech investing wouldn’t be nearly as profitable without the “tech.”

The article 3 Companies That Put the “Tech” in “Biotech” originally appeared on Fool.com and is written by Keith Speights.

Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.